semaglutide cardiovascular news SELECT: Semaglutide's Impact on CVD Events Emerges Quickly Semaglutide lowers cardiovascular events even

Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors, which is thought to explain its larger average weight loss in clinical trials

Inject Slowly: Insert needle fully at 90 degrees

Mayo Clinic 2010)

Additionally, if you're experiencing symptoms such as persistent abdominal pain, blood in your stools, excessive weight loss, or any symptoms that significantly interfere with your day-to-day activities, it's important to speak with your prescribing physician, as you may need to temporarily reduce your GLP-1 dose and be screened for more serious causes of your symptoms, such as IBD or colorectal cancer

The MDP humanin similarly acts in a systemic fashion to protect neuronal and vascular systems from disease processes and toxic insults (Cohen, 2014